Is Vyvanse (lisdexamfetamine) FDA‑approved for treating mindless eating?

Vyvanse FDA Approval Status for Mindless Eating

Vyvanse (lisdexamfetamine) is NOT FDA-approved for "mindless eating" as a standalone condition, but it IS FDA-approved specifically for moderate to severe binge eating disorder (BED) in adults 1.

Understanding the Distinction

The term "mindless eating" is colloquial and does not represent a formal psychiatric diagnosis. If you're asking about:

• Binge Eating Disorder (BED): Yes, Vyvanse is FDA-approved 1
• General overeating or non-pathological eating patterns: No, not approved

FDA-Approved Indications for Vyvanse

Vyvanse has only two FDA-approved uses 1:

1. ADHD in adults and children ≥6 years
2. Moderate to severe binge eating disorder (BED) in adults only

Critical FDA Warning

Vyvanse is explicitly NOT indicated or recommended for weight loss 1. The FDA label specifically states: "VYVANSE is not for weight loss. Use of other sympathomimetic drugs for weight loss has been associated with serious cardiovascular adverse events. The safety and effectiveness of VYVANSE for the treatment of obesity have not been established."

When Vyvanse Can Be Used for Eating Behavior

Vyvanse should only be prescribed if the patient meets DSM-5 criteria for moderate to severe BED, which requires 2:

• Recurrent episodes of binge eating (eating large amounts with loss of control)
• Marked distress regarding binge eating
• Occurs at least once weekly for 3 months
• NOT associated with compensatory behaviors (purging, excessive exercise)

Treatment Algorithm per APA Guidelines

The 2023 APA guidelines provide clear direction 2:

1. First-line treatment: Eating disorder-focused cognitive-behavioral therapy (CBT) or interpersonal therapy

2. Medication consideration: APA suggests (2C rating) that adults with BED who either:

   • Prefer medication, OR
   • Have not responded to psychotherapy alone

   Should be treated with either an antidepressant OR lisdexamfetamine

Key point: Psychotherapy is recommended first; medication is a suggestion (not a strong recommendation) for specific circumstances 2.

Dosing for BED (if criteria met)

• Start: 30 mg once daily in the morning
• Titrate: Increase by 20 mg weekly
• Target: 50-70 mg daily
• Maximum: 70 mg daily
• Discontinue if binge eating does not improve 1

Critical Safety Considerations

Absolute Contraindications

Do not prescribe if patient has 1:

• Known structural cardiac abnormalities, cardiomyopathy, serious arrhythmias, or coronary artery disease
• History of substance abuse (high abuse potential - Schedule II controlled substance)
• Taking MAOIs within past 14 days

Mandatory Pre-Treatment Assessment

Before prescribing, you must 1:

• Assess cardiac disease history (personal and family history of sudden death/ventricular arrhythmia)
• Evaluate substance abuse risk
• Check blood pressure and heart rate

Common Pitfalls to Avoid

1. Do not prescribe for weight loss alone - This is off-label and contraindicated 1, 3
2. Do not prescribe for non-pathological overeating - Patient must meet full BED criteria
3. Do not skip cardiac screening - Amphetamines can cause myocardial infarction, stroke, and sudden death 3
4. Do not ignore abuse potential - This is a Schedule II stimulant with high addiction risk 1

Evidence Quality Note

While Vyvanse is FDA-approved for BED, the APA guideline rates this as only a suggestion (2C) - meaning there's greater uncertainty about the benefit-harm balance compared to psychotherapy, which receives a stronger recommendation (1C) 2. The research evidence shows efficacy in reducing binge eating days 4, 5, 6, but the mechanism appears related to appetite suppression, enhanced satiety, and possibly improved cognitive control 4, 5 rather than addressing the underlying psychological drivers of BED.

Bottom line: If your patient has true moderate-to-severe BED (not just "mindless eating"), Vyvanse is an FDA-approved option, but only after considering psychotherapy first and conducting thorough cardiac and substance abuse screening.